BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 4064048)

  • 1. Pseudouridine: a prognostic marker in non-Hodgkin's lymphomas.
    Rasmuson T; Björk GR
    Cancer Detect Prev; 1985; 8(1-2):287-90. PubMed ID: 4064048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pseudouridine: a modified nucleoside as biological marker in malignant lymphomas.
    Rasmuson T; Björk GR
    Cancer Detect Prev; 1983; 6(1-2):293-6. PubMed ID: 6883387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary excretion of pseudouridine and prognosis of patients with malignant lymphoma.
    Rasmuson T; Björk GR
    Acta Oncol; 1995; 34(1):61-7. PubMed ID: 7865238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A clinical study of the non-Hodgkin's lymphomas according to the Kiel classification (author's transl)].
    Stacher A; Heinz R; Waldner R
    Arch Geschwulstforsch; 1979; 49(8):715-30. PubMed ID: 120730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical relevance of the Kiel classification of non-Hodgkin's lymphomas (author's transl)].
    Stacher A; Heinz R; Waldner R; Böhnel J
    Wien Klin Wochenschr; 1980 Aug; 92(15):520-5. PubMed ID: 7001765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pseudouridine excretion in patients with psoriasis.
    Clemmensen OJ; Kieffer M; Sjølin KE
    Acta Derm Venereol; 1987; 67(4):310-4. PubMed ID: 2445149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary pseudouridine in patients with lymphoma: comparison with other clinical parameters.
    Masaki Y; Itoh K; Sawaki T; Karasawa H; Kawanami T; Fukushima T; Kawabata H; Wano Y; Hirose Y; Suzuki T; Sugai S; Umehara H
    Clin Chim Acta; 2006 Sep; 371(1-2):148-51. PubMed ID: 16643879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapy of malignant lymphomas].
    Huber H; Gattringer C; Lechleitner M; Gyenes T; Frommhold H; Brittinger G; Braunsteiner H
    Wien Klin Wochenschr; 1983 Feb; 95(4):93-112. PubMed ID: 6342274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary pseudouridine and beta-aminoisobutyric acid in patients with low grade urothelial tumours. Relations between excretion and tumour recurrence.
    Nyholm KK; Sjolin KE; Wolf H; Hammer M; Knudsen J; Stahl D; Nielsen HR
    Biomedicine; 1976 May; 25(3):85-7. PubMed ID: 949520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Labeling index as a prognostic marker in non-Hodgkin's lymphomas.
    Costa A; Bonadonna G; Villa E; Valagussa P; Silvestrini R
    J Natl Cancer Inst; 1981 Jan; 66(1):1-5. PubMed ID: 6935451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cytodiagnosis of malignant non-Hodgkin's lymphomas in effusions (author's transl)].
    Wünsch PH; Müller HA
    Virchows Arch B Cell Pathol Incl Mol Pathol; 1981; 36(2-3):275-90. PubMed ID: 6116340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA-grading of malignant lymphomas. II. Correlation with clinical parameters.
    Böcking A; Chatelain R; Auffermann W; Löhr GW; Reif M; Rossner R; Becker H
    Anticancer Res; 1986; 6(5):1217-23. PubMed ID: 3800328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
    Zinzani PL; Martelli M; Poletti V; Vitolo U; Gobbi PG; Chisesi T; Barosi G; Ferreri AJ; Marchetti M; Pimpinelli N; Tura S; ; ;
    Haematologica; 2008 Sep; 93(9):1364-71. PubMed ID: 18603558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Nucleolar organizer as a marker of malignancy grade and prognosis of non-Hodgkin's malignant lymphoma].
    Raĭkhlin NT; Bukaeva IA; Probatova NA; Smirnova EA; Tupitsyn NN; Sholokhova EN
    Arkh Patol; 1996; 58(4):22-8. PubMed ID: 8967858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malignant lymphoma: an update on diagnosis, staging, and management.
    Perlin E
    Prim Care; 1980 Sep; 7(3):409-22. PubMed ID: 6905202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary intestinal lymphoma: clinical and therapeutic features of 32 patients.
    Zinzani PL; Magagnoli M; Pagliani G; Bendandi M; Gherlinzoni F; Merla E; Salvucci M; Tura S
    Haematologica; 1997; 82(3):305-8. PubMed ID: 9234576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hodgkin's and non-Hodgkin's lymphoma of the head and neck.
    Urquhart A; Berg R
    Laryngoscope; 2001 Sep; 111(9):1565-9. PubMed ID: 11568605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of immunophenotype in aggressive non-Hodgkin's lymphoma.
    Tsartsidze E; Betaneli M
    Georgian Med News; 2006 May; (134):107-9. PubMed ID: 16783081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin's Lymphoma.
    Daum S; Ullrich R; Heise W; Dederke B; Foss HD; Stein H; Thiel E; Zeitz M; Riecken EO
    J Clin Oncol; 2003 Jul; 21(14):2740-6. PubMed ID: 12860953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.